Business Overview: Faeth Therapeutics, Inc. (NASDAQ: FTH)

---

Executive Summary

Faeth Therapeutics, Inc. is a clinical-stage oncology biotechnology company that emerged from the February 2026 acquisition of privately held Faeth Therapeutics by the former Sensei Biotherapeutics (renamed and re-ticketed from NASDAQ: SNSE to NASDAQ: FTH upon closing). The combined company is now built almost entirely around PIKTOR, an oral, multi-node inhibitor pairing serabelisib and sapanisertib to simultaneously hit multiple nodes of the PI3K/AKT/mTOR oncogenic pathway.

The deal closed alongside a $200 million private placement, giving the company a materially strengthened balance sheet, and was driven by encouraging early clinical data: PIKTOR reported an 80% response rate in a Phase 2 cohort of second-line endometrial cancer. The company still carries forward Sensei's legacy immuno-oncology antibody pipeline (led by solnerstotug, formerly SNS-101, targeting the VISTA checkpoint), but PIKTOR is now explicitly the lead program and the primary reason the business exists in its current form.

---

1. Core Business Model & How They Work

Faeth is a pre-commercial, clinical-stage biotech. It has no product revenue and funds itself through equity raises, licensing, and collaborations while advancing drug candidates through clinical trials toward regulatory approval:

[ In-License / Discover Candidate ] ➡️ [ Preclinical Validation ] ➡️ [ Clinical Trials (Phase 1/2/3) ] ➡️ [ Regulatory Filing (NDA/BLA) ] ➡️ [ Commercialization (not yet reached) ]

Key Operational Drivers

1. Multi-Node Pathway Inhibition: PIKTOR's core thesis is that hitting multiple nodes of the PI3K/AKT/mTOR pathway simultaneously (rather than a single node, as most approved inhibitors do) can blunt the resistance mechanisms that let tumors escape single-agent therapy.
2. In-Licensed Asset Base: Serabelisib and sapanisertib were acquired through agreements with Ravenna and Calithera; a non-essential amino acid restriction program ("NEAAR") is licensed from Cancer Research Technology; and a related PI3K combination approach is licensed from Cornell University.
3. Reverse-Merger Capital Event: The Sensei/Faeth combination was structured as an asset acquisition paired with a $200 million private placement from life-sciences investors, effectively refinancing and redirecting a public biotech shell toward Faeth's pipeline.
4. Legacy Antibody Platform: Sensei's pre-merger TMAb (conditionally active biologics) platform continues advancing solnerstotug through a Phase 1/2 VISTA-targeting trial, alongside preclinical programs SNS-102 (VSIG4), SNS-103 (CD39), and SNS-201 (a CD28 bispecific).

---

2. Pipeline Overview

---

3. Competitive Landscape

PIKTOR competes in the crowded and intensifying PI3K/AKT/mTOR pathway space:

• Approved single-node inhibitors: alpelisib, inavolisib, capivasertib, everolimus, and temsirolimus — the entrenched standard-of-care agents PIKTOR's "multi-node" positioning is designed to differentiate against.
• Pan-PI3K/mTOR inhibitors: gedatolisib (Celcuity — an IV agent with an FDA NDA under Priority Review and a PDUFA date in mid-2026) and paxalisib (Kazia — Phase 3 in glioblastoma) are the closest mechanistic analogs and the most direct near-term competitive threats.
• Mutant-PI3Kα inhibitors: zovegalisib (Relay Therapeutics), tersolisib (Eli Lilly), SNV4818 (Novartis, via its Synnovation acquisition), and OKI-219 (OnKure).
• AKT inhibitor: afuresertib (Laekna), in Phase 3 for HR+/HER2- breast cancer — direct competition for PIKTOR's planned breast cancer indication.

Faeth's own filings acknowledge that nearly all of these competitors — several backed by large pharma (Novartis, Lilly) or well-funded specialty biotechs (Celcuity, Relay, Kazia) — have greater financial resources and more established clinical and commercial infrastructure.

---

4. Strategic Strengths & Risks

Strengths

• Differentiated mechanism: Simultaneous multi-node pathway inhibition directly targets the resistance mechanisms that limit single-node inhibitors — a scientifically credible rationale rather than a "me-too" positioning.
• Early clinical signal: An 80% response rate in a Phase 2 endometrial cancer cohort is a strong early data point that attracted a $200 million financing round.
• Strengthened balance sheet: The 2026 private placement left the company with roughly $186 million in combined cash and marketable securities as of mid-2026, management guides to at least twelve months of runway.
• Pipeline optionality: The legacy Sensei antibody programs (solnerstotug and three preclinical assets) provide additional shots on goal beyond PIKTOR.

Risks

• Binary near-term catalyst: Topline Phase 2 data in endometrial cancer, expected by year-end 2026, is a single make-or-break event for the stock's near-term trajectory.
• Heavy cash burn from the merger itself: The six months ended June 30, 2026 produced a net loss of roughly $186 million, including a $133 million acquired in-process R&D charge tied to the Faeth transaction — a reminder of how expensive the pivot was.
• Crowded, better-funded competitive field: Large pharma (Novartis, Lilly) and multiple well-capitalized biotech competitors are advancing rival PI3K/AKT/mTOR-pathway and AKT-inhibitor assets toward the same indications.
• Reliance on in-licensed compounds: Serabelisib and sapanisertib were acquired via license, not discovered in-house, so Faeth's long-term economics depend on the terms of those Ravenna/Calithera agreements.
• No revenue, continued dilution risk: As a pre-commercial clinical-stage company, further equity raises are likely before (if ever) a product reaches market.

---

5. Financial Overview

---

6. Summary Conclusion

Faeth Therapeutics is effectively a newly reconstituted clinical-stage biotech, built atop a public shell (Sensei Biotherapeutics) via a February 2026 acquisition-and-financing combination, now singularly focused on proving out PIKTOR's multi-node PI3K/AKT/mTOR inhibition thesis in endometrial cancer and, eventually, breast cancer. The early 80% response rate and $200 million in fresh capital give the company real runway and a credible scientific story, but the business has no revenue, no approved product, and a field of larger, better-funded competitors chasing the same pathway. The whole investment case currently rests on one near-term event — the Phase 2 endometrial cancer topline data expected by year-end 2026 — which will determine whether PIKTOR's differentiated mechanism translates into a durable clinical and, eventually, commercial advantage.